Updated 04:07 GMT, 6 Nov 2026 SPX 7,353.73 -4.36% NDX 26,629.81 -6.36% VIX 28.18 +69.66% GOLD 4,052.70 -0.50% CL 91.83 +4.21% BTC 75,622.05 -5.95%
NAS100 26,630 −6.36% S&P 7,354 −4.36% GOLD $4,053 −0.50% BTC $75,622 −5.95% VIX 28.18 +69.66% latest tape · as of 04:07 UTC
The Screen · Industrials · Specialty Industrial Machinery

Emerson Electric logoEmerson Electric

EMR · a US exchange · USD · Market cap $95.6B · 71,000 employees

Emerson Electric Co., a technology and software company, provides various solutions in the Americas, Asia, the Middle East, Africa, and Europe.

PASS · Titan Ethical · score 82.7
162.61 USD

Price as of 5 Nov 2026Daily close, not a live quote

Screened 2026-11-05 · the tape above runs as of 04:07 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price162.61 USD at the 5 Nov 2026 close
  • Our value readFair vs our fair value, as of 5 Nov 2026
  • Our regime readAccumulation, as of 5 Nov 2026
  • Ethical screenPasses, score 82.7 out of 100
  • OptionsOpen interest leans to puts (put/call 1.24)
  • Last reviewed5 Nov 2026 (1 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $108.92 to $187.01, base estimate $162.61 (screen dated 2026-11-05).

Current read
Accumulation ?
Fair · screened 2026-11-05
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning political buying, disclosed 2026-09-25
  • Options put/call open interest 1.24, read 2026-11-05
  • Ethical passes the values gate
Price162.61 USD
Fair value162.61
Ethical score82.7/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation158.23+2.8% to today ✓Distribution gives way to Accumulation
2026-09-04Read Distribution154.72+5.1% to today Markup gives way to Distribution first Distribution read since July
2026-07-30Read Markup149.30+8.9% to today ✓Distribution gives way to Markup after an 8% rise in 4 weeks
2026-07-02Read Distribution138.12+17.7% to today First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Emerson Electric holds its Accumulation at $162.61. The statistical read favours the buyers, held for 3 days.

As held on the ledger · 2026-11-05
PhaseAccumulation
Quantitative stateThe statistical read favours the buyers, held for 3 days
Price at the screen$162.61
Valuation37.36 trailing · 23.51 forward price to earnings
Values screenPASS · score 82.7
Beta1.21
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 32.79% Below 33% Interest-bearing debt is just 32.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 11.07% Below 49% Money owed to the company is 11.1% of assets, under the 49% limit. Pass
Revenue purity 0.83% Below 5% Only 0.8% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Emerson Electric clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and almost none of its income is interest, so it passes.

Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when EMR's ethical verdict changes

Today EMR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 5 Nov 2026: moderate competitive moat, 7.00% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

108.92Conservative162.61Base case187.01Growth case 162.61Price

Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 0.0% above the base estimate.

The Street's Range
104.00Street low 180.00Street average 208.00Street high 162.61Price

Third-party analyst targets: 28 covering, consensus Buy. The average target sits +11% from the screen price.

Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $162.61, with a range of $108.92 to $187.01, dated to the 2026-11-05 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business: a moderate moat. It trades close to our $162.61 fair value, so the easy discount is gone; you would be paying up for the quality.

The fundamentals · plain-English read
Forward P/E23.5xexpensive even after accounting for its growth
Trailing P/E37.4xexpensive: the price assumes strong growth ahead
EPS, trailing4.57
EPS, forward7.26
Revenue growth+7.0%slow but positive growth
Profit margin13.8%thin but positive margins
Return on equity12.8%a solid return on shareholder capital
FCF yield3.88%
Dividend yield1.61%
Debt to equity0.68moderate, manageable leverage
Current ratio0.90below 1: short-term bills exceed liquid assets
Beta1.21moves a little more than the market
Short interest, float0.02%
52-week range122.64 - 171.25
MoatMODERATE
Market cap$95.6B
Employees71,000

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

EMR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-04 Accumulation $166.39 +0.3% Entry 23

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Accumulation $165.96 +0.6% Entry 22

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Accumulation $164.94 +0.0% Entry 21

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $164.94 +0.0% Entry 20

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $164.94 -3.4% Entry 19

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $170.74 +1.8% Entry 18

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $167.71 +3.4% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Accumulation $162.15 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Accumulation $162.15 +0.2% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164.

2026-10-14 Accumulation $161.83 +2.3% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (27 analysts) rates it buy, with a mean price target of $164.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on EMR

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in EMR's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · EMR
DateInsiderTitleTypeSharesValue
2026-03-10 KARSANBHAI SURENDRALAL LANCA Chief Executive Officer 5,700 $811,227
2026-03-09 KRISHNAN RAM R, Chief Operating Officer 6,680 ·
2026-02-10 LEVATICH MATTHEW S Director 1,476 $239,349
2026-02-09 PIAZZA NICHOLAS J Officer 6,703 $1,066,245
2026-02-05 KARSANBHAI SURENDRALAL LANCA Chief Executive Officer 5,578 ·
2026-02-05 BLINN MARK A Director 2,876 $438,930
2026-02-03 LEE LORI M Director 1,251 ·
2026-02-03 TURLEY JAMES S Director 1,251 ·
2026-02-03 FLACH GLORIA A Director 1,251 ·
2026-02-03 BOLTEN JOSHUA B Director 1,251 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming EMR
DatePoliticianPartyTypeAmount
2026-09-25 Ro Khanna Democrat buy 1K–15K
2026-09-25 Ro Khanna Democrat buy 1K–15K
2026-09-25 Ro Khanna Democrat buy 1K–15K
2026-09-17 Kevin Hern Republican sell 15K–50K
2026-09-17 Kevin Hern Republican sell 15K–50K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $138.87 -1.0% $0.56 $994 -0.6%
2 months $143.19 -3.9% $0.56 $964 -3.6%
3 months $131.65 +4.5% $0.56 $1,049 +4.9%
6 months $138.48 -0.7% $1.11 $1,001 +0.1%
1 year $124.91 +10.1% $2.19 $1,119 +11.9%
2 years $105.11 +30.9% $4.30 $1,350 +35.0%
3 years $79.71 +72.6% $6.40 $1,806 +80.6%
5 years $87.76 +56.7% $10.52 $1,687 +68.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever EMR does next, these words stay.

Emerson Electric · EMR · Accumulation · $162.61
Recorded 2026-11-05 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.